Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope™?

Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope™?

SITC

3 years
1,138 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Launched in July of 2016, SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing Hope video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting recent FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. Through a highly informative and easy-to-understand whiteboard animated format, follow an advanced NSCLC patient who is introduced to immunotherapy and is looking to determine if it is the right treatment option for him. Companion CME/CNE Online Activity SITC is pleased to offer a CME- and CNE-certified online activity for physicians and registered nurses to complete through CME University. Presented through detailed written case studies, this activity is designed to provide physicians and registered nurses with a more in-depth overview of what they will need to know when considering and utilizing immunotherapy with NSCLC patients in the clinical setting. Inclusive of this activity is a "Frequently Asked Question" takeaway for physicians and registered nurses, which reiterates important pieces of information learned in the activity in language soluble enough to impart on patients. Physicians and Registered Nurses! Complete this activity to learn more targeted information on immunotherapy for NSCLC and claim your CE credits today! Access Here: https://www.cmeuniversity.com/course/disclaimer/113314 *This video was produced prior to the October 2016 FDA approvals of 1) TECENTRIQ® (atezolizumab, Genetech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update this video series as additional immunotherapy treatments become available.
Up Next Autoplay